Volume 65: Current Challenges in Personalized Cancer Medicine, 1st Edition

Key Features

Brought together some of the foremost basic science and clinical researchers.
Part of the renowned Advances in Pharmacology Serial
Discussion of some of the new frontiers in the development of targeted cancer therapy

Description

For this volume of Advances in Pharmacology we have brought together some of the foremost basic science and clinical researchers to discuss some of the new frontiers in the development of targeted cancer therapy. Although still in its formative stages, the development of targeted cancer therapies has already shown incredible promise in a limited number of cancer types. As basic cancer research and drug development continues, we expect this number to grow and more patients to benefit from these exciting advances. Through better patient selection and novel strategies to manage resistance, a future can be envisaged in which cancer can be reduced to the level of a chronic, manageable disease.

Readership

Pharmacologists, immunologists, and biochemists

Current Challenges in Personalized Cancer Medicine, 1st Edition

1. Vertical pathway targeting in cancer therapy

David Shahbazian, Joshua Sznol and Harriet M. Kluger

2. Histone Deacetylases (HDACs) as Mediators of Resistance to Apoptosis in Melanoma and as Targets for Combination Therapy with Selective BRAF Inhibitors

Fritz Lai, Lei Jin, Stuart Gallagher, Branka Mijatov, Xu Dong Zhang and Peter Hersey

3. Targeting the tumor stroma as a novel treatment strategy for breast cancer - shifting from the neoplastic cell-centric to a stroma-centric paradigm

Julia Tchou, Jose Conejo-Garcia

4. Targeting the Metabolic Microenvironment of Tumors

Kate M. Bailey, Jonathan W. Wojtkowiak, Arig Ibrahim Hashim and Robert J. Gillies

5. Targeted Therapy for Matastasis

Michael A. Davies

6. Emerging Strategies for Targeting Cell Adhesion in Multiple Myeloma

Rajesh R Nair, Anthony W Gebhard, Michael F Emmons and Lori A Hazlehurst

7. Targeting Notch Signaling for Cancer Therapeutic Intervention

Hongwei Shao, Qinghua Huang and Zhao-Jun Liu

8. Stem-like cells and therapy resistance in squamous cell carcinomas

Nicole Facompre, Hiroshi Nakagawa and Meenhard Herlyn, Devraj Basu

9. Targeting the tumor stroma as a novel therapeutic approach for prostate cancer

Omar E. Franco

10. Resistance to chemotherapy: short-term drug tolerance and stem cell-like subpopulations

Kevin J. Basile and Andrew E. Aplin

11. Intratumoral Heterogeneity as a Therapy Resistance Mechanism: Role of Melanoma Subpopulations

Rajasekharan Somasundaram, Jessie Villanueva and Meenhard Herlyn

12. Chemoprevention of Melanoma

SubbaRao V. Madhunapantula and Gavin P. Robertson

13. Whole genome and exome sequencing of melanoma: a step toward personalised targeted therapy

Ken Dutton-Regester and Nicholas K. Hayward

14. Targeted Therapy for Gastric Adenocarcinoma

Khaldoun Almhanna

15. HSP90 Inhibitors for Cancer Therapy and Overcoming Drug Resistance

Komal Jhaveri and Shanu Modi

16. Apoptosis in Targeted Therapy Responses: The Role of BIM

Anthony C. Faber, Hiromichi Ebi, Carlotta Costa and Jeffrey A. Engelman